197 related articles for article (PubMed ID: 22046416)
1. Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model.
Douaud M; Feve K; Pituello F; Gourichon D; Boitard S; Leguern E; Coquerelle G; Vieaud A; Batini C; Naquet R; Vignal A; Tixier-Boichard M; Pitel F
PLoS One; 2011; 6(10):e26932. PubMed ID: 22046416
[TBL] [Abstract][Full Text] [Related]
2. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Serajee FJ; Huq AM
Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
[TBL] [Abstract][Full Text] [Related]
3. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
[TBL] [Abstract][Full Text] [Related]
4. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
[TBL] [Abstract][Full Text] [Related]
5. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy.
Menten-Dedoyart C; Serrano Navacerrada ME; Bartholome O; Sánchez Gil J; Neirinckx V; Wislet S; Becker G; Plenevaux A; Van den Ackerveken P; Rogister B
PLoS One; 2016; 11(11):e0166525. PubMed ID: 27861538
[TBL] [Abstract][Full Text] [Related]
7. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis.
Ohno Y; Tokudome K
CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712
[TBL] [Abstract][Full Text] [Related]
9. Broadening the phenotypic spectrum of the presumably epilepsy-related SV2A gene variants.
Badura-Stronka M; Kuszel Ł; Wencel-Warot A; Cudnoch K; Wołyńska K; Rutkowska K; Steinborn B; Płoski R
Epilepsy Res; 2023 Feb; 190():107101. PubMed ID: 36758444
[TBL] [Abstract][Full Text] [Related]
10. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy].
Tokudome K; Shimizu S; Serikawa T; Ohno Y
Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097
[TBL] [Abstract][Full Text] [Related]
11. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
[TBL] [Abstract][Full Text] [Related]
12. An Epilepsy-Associated SV2A Mutation Disrupts Synaptotagmin-1 Expression and Activity-Dependent Trafficking.
Harper CB; Small C; Davenport EC; Low DW; Smillie KJ; Martínez-Mármol R; Meunier FA; Cousin MA
J Neurosci; 2020 Jun; 40(23):4586-4595. PubMed ID: 32341095
[TBL] [Abstract][Full Text] [Related]
13. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats.
Shi J; Zhou F; Wang LK; Wu GF
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628
[TBL] [Abstract][Full Text] [Related]
14. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of synaptic vesicle protein 2A after status epilepticus and during epilepsy in a lithium-pilocarpine model.
Contreras-García IJ; Pichardo-Macías LA; Santana-Gómez CE; Sánchez-Huerta K; Ramírez-Hernández R; Gómez-González B; Rocha L; Mendoza Torreblanca JG
Epilepsy Behav; 2018 Nov; 88():283-294. PubMed ID: 30336420
[TBL] [Abstract][Full Text] [Related]
16. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
[TBL] [Abstract][Full Text] [Related]
17. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).
Crowder KM; Gunther JM; Jones TA; Hale BD; Zhang HZ; Peterson MR; Scheller RH; Chavkin C; Bajjalieh SM
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):15268-73. PubMed ID: 10611374
[TBL] [Abstract][Full Text] [Related]
18. Connectivity Mapping Using a Novel
Zhang Y; Heylen L; Partoens M; Mills JD; Kaminski RM; Godard P; Gillard M; de Witte PAM; Siekierska A
Front Mol Neurosci; 2022; 15():881933. PubMed ID: 35686059
[TBL] [Abstract][Full Text] [Related]
19. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
Gillard M; Fuks B; Leclercq K; Matagne A
Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
[TBL] [Abstract][Full Text] [Related]
20. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
